A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed
    • Study completion moved earlier from Aug 2026 to May 19, 2026
    v11
  2. Primary completion moved earlier from Aug 2026 to Mar 19, 2026
    • Enrollment target: estimated 300 to confirmed 308
    v10
  3. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 27 to 25
    v9
  4. Re-verified, no change to tracked fieldsv8
  5. Site contacts updated at 10 of 27 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Site details revised at 1 of 27 sitesv5
  3. Site details revised at 2 of 27 sitesv4
  4. Site details revised at 3 of 27 sitesv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 27
    • Start date changed from estimate of Feb 2025 to Feb 6, 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Trial Details
NCT Number NCT06817356
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Alcohol Use Disorder
Related terms Alcoholism
Enrollment 308 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov